Compare Medpace Holdings Inc (MEDP) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Tesla, Inc. — how do they compare? Medpace Holdings Inc trades at $599.87 (market cap $16.90B), while Tesla, Inc. trades at $327.47 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 77.5× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| MEDP | TSLA | |
|---|---|---|
Market Cap | $16.90B | $1.31T |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $489.88 |
52-Week Low | $393.42 | $298.16 |
Enterprise Value | $16.52B | $1.29T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Tesla (TSLA) trades at $326.95, down 1.18% on the day, amid a bearish technical signal and mixed fundamentals. The stock faces pressure from a recent earnings miss in Q2 2026 but maintains strong operating cash flow of $14.75B in 2025. Recent news highlights regulatory approval for its driver-assistance software in Europe (Reuters, 2026-04-10) and a surge in German registrations, though competition and valuation concerns persist.
Outlook remains bifurcated: long-term growth hinges on AI and autonomy execution, but near-term risks include high P/E of 308.16 and softening auto demand. Analyst consensus price target of $393.87 suggests upside potential if innovation milestones are met, yet investor patience is required amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
